Skip to main content

NEW YORK (TheStreet) -- Ocular Therapeutix (OCUL) - Get Ocular Therapeutix Inc Report stock is up 29.71% to $8.06 on heavy trading volume on Wednesday after the company said it was preparing to launch two Phase 3 trials for its glaucoma and ocular hypertension treatments. 

The Bedford, MA-based bio-pharmaceutical company, which specializes in eye treatments, will launch the trials during the 2016 third quarter. 

Both glaucoma and ocular hypertension are chronic diseases that can cause irreversible vision loss, Ocular said. 

So far today, 3.38 million shares of Ocular have traded, versus the company's 30-day average of about 242,000 shares. 

Separately, recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

TheStreet Recommends

TheStreet Ratings rates this stock as a "sell" with a ratings score of D. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself.

You can view the full analysis from the report here: OCUL

Image placeholder title

OCUL

data by

YCharts